Graft Polymer (UK) - Research and development update

Solvonis Therapeutics

04/10/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241004:nRSD9004Ga&default-theme=true

RNS Number : 9004G  Graft Polymer (UK) PLC  04 October 2024

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM
BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF
THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE
INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

04 October 2024

Graft Polymer Selects Eurofins Discovery for Pharmacology Testing in Joint
Pre-Clinical Programme

 

Graft Polymer (UK) Plc (LON: GPL) (the "Company"), an innovative biotechnology
company co-developing therapeutics for mental health disorders, is pleased to
announce the selection of Eurofins Discovery ("Eurofins") to carry out initial
pharmacology testing for its co-lead aminoindane series. This testing will
begin immediately.

 

This programme is being developed under the collaboration agreement with Awakn
Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF) ("Awakn"), which was first
announced on 18 July 2024. The focus of this joint programme is the
development of next-generation medicines targeting trauma-related mental
health conditions, such as Post-Traumatic Stress Disorder ("PTSD"), a
condition affecting approximately 13 million adults in the U.S. and 20 million
individuals across the US, UK, and key European markets.

 

Eurofins Discovery, a leading global provider of drug discovery products and
services, will conduct tests on Graft Polymer's co-lead aminoindane series,
specifically assessing its potential for serotonin, dopamine, and
noradrenaline reuptake inhibition. This phase marks a significant milestone in
the programme, following the successful synthesis of the co-lead series, as
announced on 28 August 2024.

 

Anthony Tennyson CEO of Graft Polymer, commented: "We are pleased with this
development, Eurofins is an industry leader in drug discovery research. This
marks an important step in our mission to bring new and innovative solutions
to those suffering from trauma-related mental health disorders like PTSD. The
expertise of Eurofins, combined with our collaborative approach with Awakn,
puts us in an excellent position to advance this pre-clinical programme
swiftly and effectively."

 

Professor David Nutt, Senior Scientific Advisor at Graft Polymer, added: "The
aminoindane series being developed shows great promise in modulating key
neurotransmitter systems involved in mental health conditions like PTSD. By
targeting serotonin, dopamine, and noradrenaline reuptake, this
pharmacological testing could unlock new therapeutic pathways for addressing
trauma-related disorders. We look forward to seeing the outcomes of this
crucial pre-clinical stage."

 

 

Enquiries:

Graft Polymer (UK) Plc

Anthony Tennyson, CEO and Executive Director.
anthonytennyson@graftpolymer.co.uk

 

Allenby Capital (Broker) +44 (0) 20 3328 5656

Nick Naylor / Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)

 

 

About Graft Polymer (UK) Plc

 

Graft Polymer (UK) Plc is an innovative biotechnology company focused on
developing intellectual property relating to the treatment of mental health
and substance use disorders, and the co-development of therapeutics for mental
health disorders.  Our mission is to improve outcomes for individuals
suffering from these conditions, with an initial focus on trauma-related
mental health disorders, such as PTSD, which affects approximately 13 million
adults in the U.S. and 20 million in US, UK, and key EU  markets.

 

For more information, please visit www.graftpolymer.co.uk.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDEAKEDESELFFA